Homeopathic Drug Morbillinum Recalled for Manufacturing Practice Deviations
Washington Homeopathic Products is recalling Morbillinum in multiple potencies due to manufacturing practice deviations. No illnesses have been reported.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class II recall initiated voluntarily with no reported illnesses or injuries. The hazard is manufacturing practice deviations—a regulatory compliance issue without confirmed product defect or harm. Per the severity rubric, voluntary precautionary recalls without incident reports score 2 (Moderate).
Plain-English summary
Washington Homeopathic Products, Inc. is recalling Morbillinum in multiple potencies (7C, 8C, 9C, 10C, 12C, 13C, 15C, 20C, 21C, 30C, and 200C) in liquid pellet form due to current Good Manufacturing Practice (cGMP) deviations. The affected product was distributed nationwide in the United States.
The recall was initiated voluntarily by the firm via letter notification. Lots 20307 and 20309 are involved. The manufacturer notified the FDA of manufacturing deviations on May 13, 2022, and the FDA officially classified the recall on June 10, 2022.
No illnesses or injuries have been reported in connection with this product. Consumers who have purchased the affected Morbillinum should discontinue use. Those with questions or concerns should contact Washington Homeopathic Products, Inc. at 260 J R Hawvermale Way, Berkeley Springs, WV 25411. The FDA terminated this recall on May 25, 2023.
The recalled product
- Product
- Morbillinum, Potency:7C, 8C, 9C, 10C 12C, 13C, 15C, 20C, 21C, 30C, 200 C,Liquid Pellets, OTC, Washington Homeopathic Products, 260 JR Hawvermale Way, Berkeley Springs, WV 25411
- Manufacturer
- Washington Homeopathic Products, Inc.
- Category
- Drug — Homeopathic
- Hazard
- cgmp-deviation
- manufacturing-quality
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot# 20307
- 20309
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModeratePovi-One Povidone-Iodine 10% Topical Drug Recall for Sub Potency
FDA (Drugs) · 2026-07-01
- ModerateSensipar cinacalcet hydrochloride tablets recalled for CGMP deviations
FDA (Drugs) · 2026-07-01
- ModerateSensipar Cinacalcet Tablets Recalled Due to CGMP Deviations
FDA (Drugs) · 2026-07-01
- ModerateSensipar (Cinacalcet Hydrochloride) Tablets Recalled for CGMP Deviations
FDA (Drugs) · 2026-07-01